Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

Chlorambucil_2_Obinutuzumab

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia Chlorambucil (2 day)-Obinutuzumab (6 cycles) Regimen • CLL – Chlorambucil (2 day)-Obinutuzumab Indication • The first line treatment of CLL in those wit
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Chlorambucil-2-Obinutuzumab.pdf

Chlorambucil_14_Obinutuzumab

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia Chlorambucil (14 day)-Obinutuzumab (6 cycles) Regimen • CLL – Chlorambucil (14 day)-Obinutuzumab Indication • The first line treatment of CLL in those w
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Chlorambucil-14-Obinutuzumab.pdf

BEACON protocol v8.0 07Mar2023 signed

Description: A randomised phase IIb trial of BE AC v izumab added to Temozolomide O ± Irin tecan for children with N refractory
Url: /Media/UHS-website-2019/Docs/PaediatricOncology/beacon-protocol-v8.0-07mar2023-signed.pdf

PV-CHP Cyclophosphamide-doxorubicin-polatuzumab vedotin -prednisolone

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-DOXORUBICIN-POLATUZUMAB VEDOTIN-PREDNISOLONE- RITUXIMAB Regimen • Lymphoma – Cyclophosphamide-doxorubicin-polatuzumab vedotin -prednisolone – rituxima
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/PV-CHP-Cyclophosphamide-doxorubicin-polatuzumab-vedotin-prednisolone.pdf

ObinutuzumabVenetoclax LowRisk

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia Obinutuzumab-Venetoclax (Low Risk) Regimen • CLL – Obinutuzumab-Venetoclax (Low Risk) Indication • Chronic lymphatic leukaemia (CLL) or small lymphocyti
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/ObinutuzumabVenetoclax-LowRisk.pdf

MPF12 HaemOnc request form v10

Description: UHS LAB USE Specimen(s) received (central): BMT / Slides / BMA EDTA / PB EDTA / Cyto / other Specimen(s) distribution: Histo MGG
Url: /Media/UHS-website-2019/Docs/Health-professionals/Pathology/MPF12-HaemOnc-request-form.docx

Rituximab SC (8 weekly) Ver 1

Description: Chemotherapy Protocol LYMPHOMA RITUXIMAB SC (8 weekly) Regimen Lymphoma – Rituximab SC (8 weekly) Indication Maintenance single agent therapy in previously untreated follicular lympho
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-SC-8-weekly-Ver-1.pdf

Rituximab SC (12 weekly) Ver1

Description: Chemotherapy Protocol LYMPHOMA RITUXIMAB SC (12 weekly) Regimen Lymphoma – Rituximab SC (12 weekly) Indication Maintenance single agent therapy in relapsed / refractory follicular lym
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-SC-12-weekly-Ver1.pdf

Rituximab (8 weekly)

Description: Chemotherapy Protocol LYMPHOMA RITUXIMAB (8 Weekly) Regimen Lymphoma – Rituximab (8 weekly) Indication Non-Hodgkin’s Lymphoma as first-line maintenance therapy for previously untreated ad
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-8-weekly.pdf

Rituximab (12 weekly)

Description: Chemotherapy Protocol LYMPHOMA RITUXIMAB (12 weekly) Regimen Lymphoma – Rituximab (12 Weekly) Indication Non- Hodgkin’s Lymphoma as maintenance monotherapy for relapsed stage III or I
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-12-weekly.pdf

21 to 30 of 127

Previous 1 2 3 4 5 … Next